RxDoctor Payments Data

Paul Balliet, OD

Optometrist · Bismarck, NDNPI 1174560080

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,500 of the $2,407 with a category attached, or 62.3%. Alcon accounts for 67.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,676, 2.9 times the $584 reported in 2019. Among optometrist clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,407in general payments, 2019–2025

Across 16 payments — averaging $150.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Coopervision Inc.$500
  • Bausch & Lomb Americas Inc.$216
  • Glaukos Corporation$27
  • Dompe US, Inc.$20
  • Novartis$20
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$50021%
  • Speaking & faculty fees$1,50062%
  • Food & beverage$40717%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,407 in reported general payments places this provider in the 90th percentile of 179 optometrist providers in North Dakota.

See all optometrist providers in North Dakota

Medicare billing

Part B allowed, 2024
$74,071
Medicare patients
576
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost39$852
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$273

Paid to pharmacies, not to this prescriber.

Other optometrist in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →